What Panadol Night Treats: Main Uses and Benefits

---

The primary therapeutic use of this combination medication is addressing symptoms related to physical discomfort that may interfere with rest. The product is used to help with the temporary relief for mild to moderate aches and pains associated with accompanying sleeplessness. This dual action is considered relevant in situations where pain is the main factor causing sleeplessness.

The medication is applied to ease symptom clusters across various common discomforts, including headache, backache, muscular aches, and period pain. Furthermore, it is commonly used across conditions presenting with acute episodes where supportive symptom management is appropriate, such as easing aches and fever that may occur together during conditions like a common cold or flu. The primary therapeutic focus is on easing discomfort and supporting the ability to sleep. This medication supports the patient during difficult episodes by easing distress and contributing to improved comfort.

Quick Fact: Symptomatic Relief Context
Symptom Category: Mild to moderate pain accompanied by difficulty sleeping.
Primary Benefit: Provides dual support: analgesic relief and aids drowsiness.
Context: Used for short-term, episodic symptomatic relief.

Regulatory References

1. DailyMed: ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE tablet uses

Eligibility Map: Who can and cannot use Panadol Night

This information reflects governmental regulatory documents regarding official eligibility for Panadol Night (which contains paracetamol and diphenhydramine hydrochloride).

---

Populations That Must Not Use This Medicine (Contraindications)

Category	Contraindication Criteria
Allergy	Known or suspected hypersensitivity to paracetamol, diphenhydramine, or any other ingredient.
Age	Children under 12 years of age.
Physiological State	Breastfeeding women.
Pre-existing Conditions	Narrow-angle glaucoma, porphyria, or conditions causing obstruction in the stomach, gut, or urinary tract (e.g., prostatic hypertrophy).
Drug-Drug Interaction	Patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or who have taken them within the last two weeks.
Over-the-Counter Co-use	Patients who have taken another medicine containing paracetamol in the last 4 hours.

---

Restricted Use and Special Consideration

Use is generally not recommended or requires special caution for patients with severe liver or kidney disease/impairment, epilepsy, asthma, severe infection, or severe malnutrition. Elderly patients, particularly those with confusion, should not be given this medicine.

Interactions with other medicines and products

Regulatory documentation defines specific restrictions for co-administration due to the dual ingredients, Acetaminophen and Diphenhydramine. A primary restriction is the prohibition of co-administering the product with any other medicine containing either Acetaminophen or Diphenhydramine to prevent additive toxicological exposure and overdose risk.

Pharmacodynamic and Toxicological Interactions

The profile is structured around the potential for additive effects and exposure alteration. Co-administration with Central Nervous System (CNS) Depressants (including hypnotics, sedatives, and Codeine) may potentiate the sedative action of Diphenhydramine. Similarly, Anticholinergic drugs and Monoamine Oxidase Inhibitors (MAOIs) carry a documented risk of intensifying antimuscarinic effects, with MAOIs requiring caution for up to two weeks after discontinuation.

Interacting Substance/Class	Official Interaction Description
Coumarin Anticoagulants (e.g., Warfarin)	Prolonged regular daily use of Acetaminophen enhances the anticoagulant effect, increasing bleeding risk.
Flucloxacillin	Documented association with high anion gap metabolic acidosis.
Alcohol	Consumption of three or more drinks per day increases the risk of severe liver damage and potentiation of sedation.
CYP2D6 Substrates	Diphenhydramine is noted as a CYP2D6 isoenzyme inhibitor, affecting the clearance of co-administered substrates (e.g., Metoprolol).

Furthermore, official labeling flags a greater hazard of Acetaminophen overdose in populations with non-cirrhotic alcoholic liver disease.

The action of this fixed-dose combination is achieved through two complementary pharmacological mechanisms that target distinct biological systems to produce its distinct physiological effects.

---

Central Modulation of Pain Signaling and Thermoregulation

This domain describes the primary role of Acetaminophen, which functions by selectively inhibiting Cyclooxygenase (COX) enzymes within the Central Nervous System (CNS). This interaction reduces the synthesis of prostaglandin E2 ( PGE2) in the hypothalamus, which acts to reset the body's thermoregulatory center. This molecular step modifies nociceptive signaling and results in the physiological reduction of elevated body temperature, thereby affecting two pathways involved in physiological arousal.

---

Targeted Blockade of Central Arousal Pathways

This domain covers the mechanism of Diphenhydramine hydrochloride. The action involves competitive antagonism of the Histamine H1-receptors ( H1 R) found in the brain's Reticular Activating System (RAS). Histamine is a key neurotransmitter in the arousal system; by blocking its receptor, the drug suppresses the excitatory signaling required for wakefulness. This targeted pathway interference induces a state of somnolence, which modulates activity within the central arousal system.

The administration of Panadol Night is defined by a set of instructions focusing on time-dependent, single-dose oral use. The medication is an oral formulation and must be swallowed whole with water.

Official Dosing and Frequency

User Group	Single Dose	Maximum Daily Dose
Adults and Adolescents (ge 16 years)	Two tablets (1000 mg Paracetamol / 50 mg Diphenhydramine HCl)	Two tablets (one single dose) in 24 hours
Adolescents (12 to 15 years)	One tablet (500 mg Paracetamol / 25 mg Diphenhydramine HCl)	One tablet in 24 hours
Children (< 12 years)	Not permitted	Not permitted

The required dosing frequency is once daily, taken only when necessary to support rest. The dose should be administered approximately 20 minutes before bedtime to align with the somniferous component.

Administration Constraints and Duration

The product is explicitly intended for short-term use only. Continuous use must not exceed seven consecutive nights without consulting a health professional.

A critical procedural constraint is managing the total intake of paracetamol. A minimum interval of four hours is required between taking this nighttime product and any other medication containing paracetamol. Furthermore, the total combined intake of paracetamol from all sources must not exceed 4000 mg in any 24-hour period. For individuals with existing hepatic or renal impairment, it is recommended to reduce the standard dose and increase the interval between doses to at least 6 to 8 hours.

Research evidence / Overview of studies

This section summarizes research that explored the evaluation metrics related to inflammation and symptoms in patients with temporary pain and accompanying sleeplessness. The findings from clinical studies focus on measures of disease activity, metrics of joint function, and general patient well-being.

---

Key Study Findings

Research evaluated measures of joint function and the severity of morning stiffness in patients with pain. This included assessing the time required for a patient to achieve maximum joint flexibility after waking. The dual-component formulation combines paracetamol (acetaminophen) for its analgesic and antipyretic effects with diphenhydramine hydrochloride, a first-generation antihistamine with known sedative properties.

• Sleep Quality Metrics: Studies have assessed subjective sleep parameters, such as the time needed to fall asleep and overall perceived sleep quality, in adult populations experiencing pain-related sleep disturbances.
• Inflammatory Markers: Studies have consistently assessed measures of erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP), both key markers of inflammation, in relation to the paracetamol component.
• Symptom Resolution: Research focused on the duration of symptomatic relief provided by the analgesic component and the accompanying sedation from the antihistamine component.

---

Studies Evaluating Specific Patient Groups

Diphenhydramine is widely used as a component in non-prescription sleep aids. The clinical evidence for these combination products generally supports short-term use for occasional disturbed sleep. Tolerance to the sedative effects may develop with continued use.

• Elderly Patients: Studies included evaluations in individuals aged 65 and older, examining pharmacokinetics. Certain findings have been reported regarding the potential for greater adverse effects from diphenhydramine in this age group.
• Liver Impairment: Research has included evaluations in individuals with severe liver impairment, with studies focusing on monitoring hepatic function metrics related to paracetamol metabolism.

Common questions about Panadol Night (FAQ)

Q: How quickly does Panadol Night usually start to work?

A: Official product information indicates that the pain relief component (paracetamol) typically begins to work within 30 minutes. The sleep-inducing component (diphenhydramine) is intended to start working approximately 20 minutes after administration, which is why it is specified to be taken shortly before bedtime.

Q: Why do some people say Panadol Night makes them feel groggy the next day?

A: Regulatory safety profiles recognize that effects such as drowsiness or sedation may sometimes persist into the following day. This is described as a potential residual effect of the antihistamine component, meaning the sedative effect might take longer to fully wear off for some individuals.

Q: Can Panadol Night be used by people with long-term pain conditions?

A: Regulatory documents state that this medicine is explicitly intended for short-term use only and is not formulated for chronic conditions. Official instructions state that continuous use must not exceed seven consecutive nights without consulting a health professional.

Q: Are there any common foods or drinks that interact with Panadol Night?

A: Regulatory information specifically highlights the potential interaction with alcohol. Official warnings state that consuming three or more alcoholic drinks per day may increase the risk of liver damage and potentiation of sedation. No other common foods or non-alcoholic drinks are typically singled out for critical interaction in the regulatory documentation.

Q: Do regulatory bodies classify Panadol Night as generally safe for short-term use?

A: Official documents define this product for short-term use only and include detailed instructions and warnings for its proper use within this limited time frame. Adherence to the stated limits and dosage restrictions is specified in regulatory documents to mitigate safety risks associated with the active ingredients.

Q: What is the expected duration of the sedative effect of Panadol Night?

A: The somniferous (sleep-inducing) effect is derived from the antihistamine component (diphenhydramine). Official information describes this component as generally lasting for a duration that supports an adequate night's sleep.

Q: Does Panadol Night interact with common antidepressants?

A: The official interaction profile lists restrictions on co-administration with Monoamine Oxidase Inhibitors (MAOIs), a class of antidepressant. Additionally, official labeling includes caution regarding any medicine that causes Central Nervous System (CNS) depression, as this may potentiate the sedative effects of Panadol Night.

Q: Is Panadol Night considered a sleeping pill?

A: Panadol Night is classified as an analgesic-antipyretic combined with a first-generation mathbfH1 antihistamine. The antihistamine component has somniferous (sleep-inducing) properties, which is why it functions as a component in non-prescription sleep aids.

Q: Can Panadol Night affect how I feel when I wake up?

A: Official safety information notes that patients may experience effects such as drowsiness, sedation, or dizziness. These effects may occasionally persist and affect how one feels upon waking, as described in the product’s safety profile.

Q: Are there any documented cases of allergic reactions to Panadol Night?

A: Known hypersensitivity to the active ingredients is a contraindication to use, as noted in official documents. Furthermore, regulatory labeling includes warnings for the potential occurrence of Severe Cutaneous Adverse Reactions (SCARs), though specific frequency details are not typically provided in this context.

Q: If I am taking prescribed medication for anxiety, can I use Panadol Night?

A: Official regulatory documents list co-administration with other Central Nervous System (CNS) depressants as restricted. This is due to the potential risk of potentiating the sedative effects of the antihistamine component in Panadol Night.

Q: Can Panadol Night be used during pregnancy or breastfeeding?

A: The use of this medicine is generally not recommended during pregnancy. It is explicitly listed as contraindicated for women who are currently breastfeeding due to potential risks to the infant.

Q: Can I take Panadol Night if I have a common cold?

A: The medicine's stated function is the relief of mild to moderate pain that is interfering with sleep. When taking the medicine for cold-related pain, label information includes caution to ensure no other medicines taken for cold or flu symptoms contain either paracetamol or diphenhydramine.

Q: What should I do if I think I've had a bad reaction to Panadol Night?

A: Regulatory guidance describes the process for reporting adverse reactions through a healthcare professional or directly to their national health regulatory authority. This allows for the ongoing collection of safety information.

Q: Do the effects of Panadol Night last through the entire night?

A: The product is designed to provide symptomatic relief and promote drowsiness for a duration that supports an adequate night's sleep. This is achieved through the action of the long-acting antihistamine component.

Q: Is Panadol Night addictive?

A: Official documents note that tolerance to the sedative effects of the antihistamine component may develop with continued use. However, the product is not categorized as a controlled substance with known high potential for abuse or dependence.

Q: Is Panadol Night suitable for travelers dealing with jet lag?

A: The approved use for this medicine is the symptomatic relief of mild to moderate pain that concurrently interferes with the ability to sleep. Regulatory documents do not list jet lag as an approved therapeutic indication.

Official Storage and Disposal Requirements

Regulatory documents define specific conditions for storing and disposing of this medicine to maintain its stability and ensure safety.

Storage Conditions

Requirement	Details
Temperature & Environment	Store below 25 C or 30 C in a dry place. Protect from light and moisture.
Packaging	Keep in the original packaging until use. Do not store in the car, bathroom, or near a sink.
Child Safety	Keep strictly out of the sight and reach of children. A locked, elevated cupboard is recommended.
Stability	Do not use the medicine after the expiration date (EXP) printed on the pack.

Disposal Protocol

Unused or expired medicine must not be disposed of via household waste or flushed down the toilet or sink. To ensure environmental protection, return all unwanted product to a pharmacist for appropriate disposal.